Clinical trials
HIV clinical trials
Below are recruiting hiv clinical trials, each written for real people, not researchers. We’re tracking 611 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07181486RecruitingPhase 1
Safety study of a vaginal gel for healthy women
This trial tests a gel placed in the vagina to see if it is safe. Healthy women with regular periods who have a steady partner may join.
San Francisco, CaliforniaAges 18–45 - NCT06485154RecruitingPhase 4
Finding the best HIV treatment after PrEP shot failure
This trial is for people who got exposed to HIV despite taking the long-acting PrEP shot (cabotegravir). It tests different pill-based HIV treatment plans to find the best option for them.
Johannesburg, GautengAges 15 years+ - NCT06631365RecruitingPhase 2
PrEP on demand: a pilot study for men who have sex with men
This study tests a '2-1-1' on-demand PrEP strategy for cisgender men who have sex with men. It aims to see if taking PrEP only around the time of sex is safe and effective. If you are interested in starting or currently taking PrEP this way, you may be eligible.
San Francisco, CaliforniaAges 18 years+ - NCT06037564Enrolling by invitationPhase 4
Switching HIV treatment to a simpler daily pill
This study tests whether switching your current HIV medication to a daily pill with doravirine, dolutegravir, and lamivudine is safe and effective. It is for people whose HIV is well-controlled but who have had to change treatment before because it stopped working.
Aarau, Canton of AargauAges 18 years+ - NCT07467018Recruiting
Mobile van study of a long-acting HIV prevention shot
This study tests if giving a long-acting HIV prevention shot (lenacapavir) from a mobile medical van can reach people at risk for HIV in Los Angeles County. You may be able to join if you are HIV negative, at risk for HIV, and are willing to try a shot instead of a daily pill.
Santa Monica, CaliforniaAges 18 years+ - NCT05529342Enrolling by invitation
Long-term follow-up for a prior gene-cell treatment
This study follows people long-term after receiving a specific gene-cell treatment called AGT103-T. It helps researchers check long-term safety and outcomes, which can guide future care for others.
Washington D.C., District of ColumbiaAges 18 years+ - NCT07438080Recruiting
HPV self-screening vs. doctor screening for anal cancer risk
This trial compares two ways to screen for HPV, a virus linked to anal cancer. People living with HIV will either collect their own sample or have a doctor do it, then switch methods. The goal is to see which is more comfortable and accurate.
Saint-PaulAges 30–65 - NCT06046079Recruiting
HIV Prevention Service Use Study in Washington DC
This study looks at how people in the Washington, DC area use HIV prevention services. It focuses on those who are HIV-negative and either new to PrEP, taking daily PrEP pills, or getting long-acting injectable PrEP.
Washington D.C., District of ColumbiaAges 18 years+ - NCT06545968Recruiting
Social media to help young people with HIV stay in care
This study tests whether a social media program can help young people with HIV in Uganda stay connected to their medical care. If you are between 15 and 24 years old and are new to care or returning after a break, you may be able to join.
MbararaAges 15 years+ - NCT06845774Enrolling by invitation
PrEP support via telehealth for people who inject drugs
This trial tests whether telehealth support can help people who inject drugs start and stay on PrEP (HIV prevention medicine). You will join several sessions and follow-up visits to see if this approach works better than standard care.
Lexington, KentuckyAges 18–99 - NCT06745050Recruiting
Motivation Matters! study for HIV treatment
This study tests a program called Motivation Matters! to help people with HIV who have traded sex for things they need get started on HIV medication and stay healthy. It uses text messages to support you.
NairobiAges 18 years+ - NCT07666386Enrolling by invitation
HIV treatment Biktarvy in early pregnancy
This trial checks if the once-daily HIV pill Biktarvy (B/F/TAF) stays safe and works well for women who are newly pregnant (up to 12 weeks). It is for women already taking Biktarvy with a controlled virus load.
Wuhan, HubeiAges 18 years+ - NCT07486661Recruiting
Preventing frailty in people with HIV aged 65-75
This study aims to help people with HIV between the ages of 65 and 75 stay healthy and avoid becoming frail as they age. It tests a program to prevent frailty and see if it works.
BrusselsAges 65–74 - NCT06904820Recruiting
Hepatitis and HIV screening for drug users
This trial tests a convenient way to screen people who use drugs or are in vulnerable situations for hepatitis B, C, and HIV using rapid tests and a liver scanner. The goal is to see if offering these tests in community settings (like shelters or mobile clinics) is acceptable and works well.
LimogesAges 18 years+ - NCT06799338Recruiting
Study of lenacapavir for HIV treatment in France
This study looks at how well lenacapavir works when added to a personalized HIV treatment plan. If you have HIV and received lenacapavir as your first dose between June 2023 and June 2024, this research may help understand its real-world effects.
Paris, Île-de-France RegionAges 18 years+ - NCT06706986Enrolling by invitation
Global registry for people with HIV who failed newer integrase inhibitors
This trial is a registry for people with HIV whose virus is no longer fully controlled by certain newer medications (integrase inhibitors). It aims to collect data to better understand why these treatments stop working and how to improve future care.
UtrechtAges Any age - NCT05630638RecruitingPhase 4
Doravirine dose testing during pregnancy for breastfeeding mothers
This study tests how to best dose doravirine for pregnant people with HIV who plan to breastfeed after delivery. The goal is to keep the HIV treatment working safely for both pregnancy and breastfeeding.
Cape TownAges 18 years+ - NCT06458504Recruiting
HIV infection and bone marrow health study
This study looks at how HIV infection affects the bone marrow's ability to make blood cells. Researchers will use bone marrow samples already taken from HIV-positive patients and compare them to samples from people without HIV.
Boulogne-BillancourtAges 18 years+ - NCT06158126RecruitingPhase 4
Pregnancy and infant health outcomes study
This study follows pregnant women and their babies to see how well HIV prevention medicines work during pregnancy. It aims to help keep both mother and baby healthy.
LilongweAges 15–55 - NCT07011563Recruiting
Helping teens & adults talk about sexual health
This study helps teens and their trusted adults have open conversations about sexual health. It's for young people ages 14 to 17 who have had oral or anal sex with another male.
Providence, Rhode IslandAges 14–17 - NCT06637436Recruiting
PrEP motivation help for men who use meth
This study tests two ways to help men who were assigned male at birth and use methamphetamine stay motivated to start PrEP, a medicine that prevents HIV. You may join if you are HIV-negative or don't know your status and haven't taken PrEP recently.
Miami, FloridaAges 18 years+ - NCT06638892Recruiting
PrEP study for Black cisgender women
This study tests ways to help Black cisgender women take PrEP, a daily pill that prevents HIV infection. It focuses on making PrEP work for you.
Durham, North CarolinaAges 18 years+ - NCT04892654RecruitingPhase 3
Doravirine plus dolutegravir switch for people with HIV
This Phase 3 study tests whether switching from a three-drug HIV regimen to a two-drug regimen (doravirine plus dolutegravir) can keep your virus levels controlled. It may help people who are stable on their current treatment explore a simpler switch under close monitoring.
LondonAges 18 years+ - NCT06800664Recruiting
Home self-sampling for cervical cancer prevention in Ghana
This study tests at-home self-sampling kits to help prevent cervical cancer in women living with HIV in Ghana. Participation is completely voluntary, involves collecting your own sample at home, and aims to make screening easier.
Cape Coast, Central RegionAges 25–65
Hear when a new HIV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for hiv?
- Yes. Clin2 currently lists 611 recruiting hiv studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a hiv trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a hiv trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.